Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Special Review

Liver disease trends in the Asia-Pacific region for the next 50 years

Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim

Clin Mol Hepatol. 2025;31(3):671-684. Published online March 4, 2025

Crossref 1

DOI: https://doi.org/10.3350/cmh.2025.0043

Reviews

Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications

Xindi Ke, Shangze Jiang, Qiaoxin Wei, Minghao Sun, Hang Sun, Mingchang Pang, Mei Liu, Lejia Sun, Huayu Yang, Yilei Mao

Clin Mol Hepatol. 2025;31(3):685-705. Published online January 22, 2025

Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.1039

Deciphering adenosine signaling in hepatocellular carcinoma: Pathways, prognostic models, and therapeutic implications

Huihai Yang, Martina Mang Leng Lei, Longfei Xie, Yinuo Shou, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(3):706-729. Published online February 5, 2025

Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.1068

Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum

Vishnu Girish, Rakhi Maiwall

Clin Mol Hepatol. 2025;31(3):730-752. Published online March 26, 2025

DOI: https://doi.org/10.3350/cmh.2024.1060

Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment

Hee Yeon Kim, Mary E. Rinella

Clin Mol Hepatol. 2025;31(3):753-770. Published online April 2, 2025

Crossref 1

DOI: https://doi.org/10.3350/cmh.2025.0083

Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease

Eiji Kakazu, Masaaki Mino, Tatsuya Kanto

Clin Mol Hepatol. 2025;31(3):771-795. Published online April 16, 2025

Crossref 1

DOI: https://doi.org/10.3350/cmh.2025.0048

Original Articles

High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease

Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao

Clin Mol Hepatol. 2025;31(3):796-809. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.0822

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial

Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang

Clin Mol Hepatol. 2025;31(3):810-822. Published online January 17, 2025

Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.0819

Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis

Jae Yeon Kim, Hyeri Park, Soo Young Park, Se Ho Kim, Ja Yun Lim, Ki Seog Lee, Si Hyun Bae, Gi Jin Kim

Clin Mol Hepatol. 2025;31(3):823-840. Published online January 22, 2025

DOI: https://doi.org/10.3350/cmh.2024.0741

Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalently closed circular DNA minichromosome

Sheng-Tao Cheng, Wei-Xian Chen, Hai-Jun Deng, Xin He, Hui Zhang, Ming Tan, Hai-Bo Yu, Zhen-Zhen Zhang, Ji-Hua Ren, Min-Li Yang, Da-Peng Zhang, Zhi-Hong Li, Juan Chen

Clin Mol Hepatol. 2025;31(3):841-865. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2024.0694

Baveno VI-SSM stratifies the risk of portal hypertensionrelated events in patients with HBV-related cirrhosis

Haiyu Wang, Weihao Liang, Ling Zhou, Jiankang Song, Biao Wen, Qiaoping Wu, Yuanjian Zhang, Xiaofeng Zhang, Haoran Ke, Yujun Tang, Fuyuan Zhou, Youfu Zhu, Weiqun Wen, Zhihua Liu, Yali Ji, Qintao Lai, Qinjun He, Wenfan Luo, Tingting Qi, Miaoxia Liu, Xiaoqin Lan, Yongpeng Chen, Ranran Xi, Junting Wan, Lin Dai, Yuan Li, Jinjun Chen

Clin Mol Hepatol. 2025;31(3):866-880. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2024.0609

Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study

Bingtian Dong, Ruiling He, Shenghong Ju, Yuping Chen, Ivica Grgurevic, Jianzhong Ma, Ying Guo, Huizhen Fan, Qiang Yan, Chuan Liu, Huixiong Xu, Anita Madir, Kristian Podrug, Jia Wang, Linxue Qian, Zhengzi Geng, Shanghao Liu, Tao Ren, Guo Zhang, Kun Wang, Meiqin Su, Fei Chen, Sumei Ma, Liting Zhang, Zhaowei Tong, Yonghe Zhou, Xin Li, Fanbin He, Hui Huan, Wenjuan Wang, Yunxiao Liang, Juan Tang, Fang Ai, Tingyu Wang, Liyun Zheng, Zhongwei Zhao, Jiansong Ji, Wei Liu, Jiaojiao Xu, Bo Liu, Xuemei Wang, Yao Zhang, Qiong Yan, Hui Liu, Xiaomei Chen, Shuhua Zhang, Yihua Wang, Yang Liu, Li Yin, Yanni Liu, Yanqing Huang, Li Bian, Ping An, Xin Zhang, Shaoting Zhang, Jinhua Shao, Xiangman Zhang, Wei Rao, Chaoxue Zhang, Christoph Frank Dietrich, Won Kim, Xiaolong Qi

Clin Mol Hepatol. 2025;31(3):881-898. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2024.0898

Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study

Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bair, Te-Sheng Chang, Chun-Yen Lin, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzeng-Hue Yang, Cheng-Yuan Peng, Chi-Chieh Yang, Lee-Won Chong, Chien-Wei Huang, Chih-Wen Lin, Cheng-Hsin Chu, Ming-Chang Tsai, Jia-Horng Kao, Chun-Jen Liu, Wan-Long Chuang, Teng-Yu Lee, Ming-Lung Yu, on behalf of TACR investigators

Clin Mol Hepatol. 2025;31(3):899-913. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2024.1015

GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma

Hyung Seok Kim, Jung Hwan Yoon, Ji Yi Choi, Moon Gyeong Yoon, Geum Ok Baek, Minji Kang, Se Ha Jang, Won Park, Yunjin Go, Jestlin Tianthing Ng, Suk Woo Nam, Jee-Yeong Jeong, Ji Eun Han, Hyo Jung Cho, Su Bin Lim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun

Clin Mol Hepatol. 2025;31(3):914-934. Published online February 6, 2025

Crossref 2

DOI: https://doi.org/10.3350/cmh.2024.1038

Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target

Gu-Wei Ji, Zheng-Gang Xu, Shuo-Chen Liu, Shu-Ya Cao, Chen-Yu Jiao, Ming Lu, Biao Zhang, Yue Yang, Qing Xu, Xiao-Feng Wu, Ke Wang, Yong-Xiang Xia, Xiang-Cheng Li, Xue-Hao Wang

Clin Mol Hepatol. 2025;31(3):935-959. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2024.0895

CD36 promotes iron accumulation and dysfunction in CD8⁺ T cells via the p38-CEBPB-TfR1 axis in earlystage hepatocellular carcinoma

Yifei Qin, Fei Huo, Zhuan Feng, Jialu Hou, Yaxin Ding, Quancheng Wang, Yu Gui, Ziwei Yang, Jiali Yang, Gang Zhou, Ling Li, Jianli Jiang, Lingmin Kong, Shijie Wang, Gang Nan, Dingqiao Xu, Xiaohang Xie, Lijuan Wang, Qian He, Ruibin Yang, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu

Clin Mol Hepatol. 2025;31(3):960-980. Published online March 4, 2025

DOI: https://doi.org/10.3350/cmh.2024.0948

Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway

Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Naoto Fujiwara, Masakatsu Tsurusaki, Kohei Hanaoka, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Atsushi Takebe, Takaaki Murase, Keiko Kamei, Takuya Nakai, Ippei Matsumoto, Kazuto Nishio, Masatoshi Kudo

Clin Mol Hepatol. 2025;31(3):981-1002. Published online March 11, 2025

DOI: https://doi.org/10.3350/cmh.2024.1088

Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues

Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Atsukawa, Hirokazu Takahashi, Kunihiko Tsuji, Koichi Takaguchi, Pei-Chien Tsai, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Eileen Yoon, Sung Eun Kim, Sang Bong Ahn, Gi-Ae Kim, Jang Han Jung, Soung Won Jeong, Hyunwoo Oh, Cheng-Hao Tseng, Masatoshi Ishigami, Angela Chau, Mayumi Maeda, Satoshi Yasuda, Makoto Chuma, Takanori Ito, Keigo Kawashima, Joanne Kimiko Liu, Adrian Gadano, Ritsuzo Kozuka, Norio Itokawa, Kaori Inoue, Tomonori Senoh, Jie Li, Wan-Long Chuang, Ramsey Cheung, Chao Wu, Ming-Lung Yu, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(3):1003-1017. Published online March 17, 2025

Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.1070

Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease

Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim

Clin Mol Hepatol. 2025;31(3):1018-1031. Published online April 4, 2025

DOI: https://doi.org/10.3350/cmh.2024.1183

MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation

Tiantian Wang, Dean Rao, Chenan Fu, Zhoubin Sun, Yiming Luo, Junli Lu, Jie Jin, Han Li, Feimu Fan, Huifang Liang, Wenjie Huang, Limin Xia

Clin Mol Hepatol. 2025;31(3):1032-1057. Published online April 11, 2025

DOI: https://doi.org/10.3350/cmh.2024.1163

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States

Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2025;31(3):1058-1070. Published online April 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0169

HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study

Vincent Wai-Sun Wong, Guy W. Neff, Adrian M. Di Bisceglie, Ru Bai, Junwei Cheng, Meng Yu, Alexander Liberman, Liping Liu, Nadege Gunn

Clin Mol Hepatol. 2025;31(3):1071-1083. Published online April 21, 2025

DOI: https://doi.org/10.3350/cmh.2025.0145

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study

Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(3):1084-1099. Published online April 23, 2025

DOI: https://doi.org/10.3350/cmh.2024.1096

Snapshot

Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease

Pingping Jin, Xinyi Lu, Daozhen Chen, Yu Chen

Clin Mol Hepatol. 2025;31(3):1100-1102. Published online February 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1090

Erratums

Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]

Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang

Clin Mol Hepatol. 2025;31(3):1103-1104. Published online July 1, 2025

DOI: https://doi.org/10.3350/cmh.2023.0051e
Corrects: Clin Mol Hepatol 2023;29(2):516

Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]

Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(3):1105-1106. Published online July 1, 2025

DOI: https://doi.org/10.3350/cmh.2024.0145e
Corrects: Clin Mol Hepatol 2024;30(3):487

Letters to the Editor

Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023

Donghee Kim, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e235-e238. Published online December 30, 2024

Crossref 3

DOI: https://doi.org/10.3350/cmh.2024.1150

What is new in the 2024 Chinese guidelines for fatty liver disease?

Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(3):e239-e246. Published online January 21, 2025

DOI: https://doi.org/10.3350/cmh.2024.1165

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai

Clin Mol Hepatol. 2025;31(3):e247-e248. Published online February 6, 2025

DOI: https://doi.org/10.3350/cmh.2025.0073

Classification of microvascular invasion of hepatocellular carcinoma: Different standards, common goals: Letter to the editor on “Classification of microvascular invasion of hepatocellular carcinoma: Correlation with prognosis and magnetic resonance imaging”

Wei Chen, Yihui Rong, Tianshi Ma, Weiwei Shi, Wei Chen, Hang Jiang

Clin Mol Hepatol. 2025;31(3):e249-e251. Published online February 18, 2025

DOI: https://doi.org/10.3350/cmh.2025.0167

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou

Clin Mol Hepatol. 2025;31(3):e252-e253. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0189

Research Letters

Mendelian randomization does not support the effects of G CSF on decompensated liver disease

Liling Li, Hui Wang, Hong Wang, Jinchang Huang

Clin Mol Hepatol. 2025;31(3):e254-e258. Published online March 4, 2025

DOI: https://doi.org/10.3350/cmh.2025.0172

Lipidomic analysis of alcohol use disorder patients revealed the biomarkers for alcohol-related liver disease susceptibility

Dongyao Wang, Hongwei Zhang, Yuxiao Tang

Clin Mol Hepatol. 2025;31(3):e259-e262. Published online April 2, 2025

Crossref 1

DOI: https://doi.org/10.3350/cmh.2025.0227

Non-infectivity of hepatitis B virus under nucleoside analog therapy revealed through auxiliary partial orthotopic liver transplantation

Xiaojie Chen, Guiwen Guan, Lin Wei, Jidong Jia, Xiangmei Chen, Fengmin Lu, Zhijun Zhu

Clin Mol Hepatol. 2025;31(3):e263-e267. Published online May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0393

Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e268-e272. Published online May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0384

Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease

Pojsakorn Danpanichkul, Donghee Kim, Benjamin Nah, Karn Wijarnpreecha, Suthat Liangpunsakul

Clin Mol Hepatol. 2025;31(3):e273-e276. Published online May 27, 2025

DOI: https://doi.org/10.3350/cmh.2025.0474

Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023

Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e277-e280. Published online May 27, 2025

DOI: https://doi.org/10.3350/cmh.2025.0548

Viewed By 12435	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7601	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7030	MAFLD: How is it different from NAFLD?
Viewed By 5648	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5498	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 348	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Previous issues